Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma
暂无分享,去创建一个
E. Ruppin | Jun S. Wei | J. Lee | L. Hermida | C. Kesserwan | Q. Jiang | Jingli Zhang | N. Nair | M. Miettinen | R. Hassan | M. Sengupta | B. Morrow | Javed Khan | A. Lebensohn | Idrees Mian | V. A. Misra | V. Misra
[1] Ash A. Alizadeh,et al. Atlas of clinically distinct cell states and ecosystems across human solid tumors , 2021, Cell.
[2] Anna L. Brown,et al. Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer , 2021, Nature Communications.
[3] A. Maconi,et al. Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma , 2021, Frontiers in Oncology.
[4] E. Ruppin,et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome , 2021, Cell.
[5] A. Mansfield,et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial , 2021, The Lancet.
[6] G. Frampton,et al. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors , 2020, JAMA network open.
[7] J. Brugarolas,et al. Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer. , 2020, Cancer discovery.
[8] C. Svendsen,et al. Immunosuppressive Functions of M2 Macrophages Derived from iPSCs of Patients with ALS and Healthy Controls , 2020, iScience.
[9] Angela N. Brooks,et al. Visualizing and interpreting cancer genomics data via the Xena platform , 2020, Nature Biotechnology.
[10] Anna L. Brown,et al. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer , 2020, Cell reports medicine.
[11] A. Greenbaum,et al. Peritoneal mesothelioma , 2020, Translational lung cancer research.
[12] E. Ruppin,et al. Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1. , 2019, JAMA oncology.
[13] G. Wainrib,et al. Deep learning-based classification of mesothelioma improves prediction of patient outcome , 2019, Nature Medicine.
[14] F. Galateau-Sallé,et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy , 2019, CA: a cancer journal for clinicians.
[15] T. Walsh,et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy , 2019, Proceedings of the National Academy of Sciences.
[16] M. Ladanyi,et al. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma , 2019, Genome Medicine.
[17] Adam A. Friedman,et al. Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy , 2018, bioRxiv.
[18] Damian Szklarczyk,et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..
[19] Andreas Ruepp,et al. CORUM: the comprehensive resource of mammalian protein complexes—2019 , 2018, Nucleic Acids Res..
[20] Xi Zhang,et al. Nucleolar and Spindle Associated Protein 1 (NUSAP1) Inhibits Cell Proliferation and Enhances Susceptibility to Epirubicin In Invasive Breast Cancer Cells by Regulating Cyclin D Kinase (CDK1) and DLGAP5 Expression , 2018, Medical science monitor : international medical journal of experimental and clinical research.
[21] David L. Gibbs,et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. , 2018, Cancer discovery.
[22] Xiaonan Wei,et al. NUSAP1 gene silencing inhibits cell proliferation, migration and invasion through inhibiting DNMT1 gene expression in human colorectal cancer , 2018, Experimental cell research.
[23] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[24] Hyojin Kim,et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions , 2017, Nucleic Acids Res..
[25] James T. Robinson,et al. Variant Review with the Integrative Genomics Viewer. , 2017, Cancer research.
[26] F. Mowat,et al. Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma , 2017, Cancer Causes & Control.
[27] L. Staudt,et al. The NCI Genomic Data Commons as an engine for precision medicine. , 2017, Blood.
[28] Ann E. Sizemore,et al. Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.
[29] P. Hieter,et al. Synthetic lethality and cancer , 2017, Nature Reviews Genetics.
[30] A. Santoro,et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2017, The Lancet. Oncology.
[31] J. Brooks,et al. NUSAP1 promotes invasion and metastasis of prostate cancer , 2017, Oncotarget.
[32] Ying Chai,et al. Prognostic role of cyclin B1 in solid tumors: a meta-analysis , 2016, Oncotarget.
[33] M. Carbone,et al. Environmental risk of mesothelioma in the United States: An emerging concern—epidemiological issues , 2016, Journal of toxicology and environmental health. Part B, Critical reviews.
[34] G. Matullo,et al. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma. , 2016, Cancer letters.
[35] Thomas D. Wu,et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.
[36] A. Farioli,et al. Radiation‐induced mesothelioma among long‐term solid cancer survivors: a longitudinal analysis of SEER database , 2016, Cancer medicine.
[37] Meagan E. Sullender,et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.
[38] Wei Zhou,et al. MTBP Promotes the Invasion and Metastasis of Hepatocellular Carcinoma by Enhancing the MDM2-Mediated Degradation of E-Cadherin , 2015, Digestive Diseases and Sciences.
[39] M. Maio,et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. , 2015, The Lancet. Respiratory medicine.
[40] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[41] N. Agarwal,et al. MTBP inhibits migration and metastasis of hepatocellular carcinoma , 2015, Clinical & Experimental Metastasis.
[42] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[43] M. Lucchi,et al. Expression status of candidate genes in mesothelioma tissues and cell lines. , 2015, Mutation research.
[44] T. Nakajima,et al. Identification of actionable mutations in malignant pleural mesothelioma. , 2014, Lung cancer.
[45] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[46] G. Ceresoli,et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. , 2014, Lung cancer.
[47] M. Maio,et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. , 2013, The Lancet. Oncology.
[48] D. Landau,et al. Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[49] M. Pagano,et al. A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis. , 2013, Trends in cell biology.
[50] N. Agarwal,et al. MTBP suppresses cell migration and filopodia formation by inhibiting ACTN4 , 2012, Oncogene.
[51] A. Musk,et al. A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[52] L. Seymour,et al. Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[53] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[54] R. Labianca,et al. Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[55] Q. Zhan,et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis. , 2008, Carcinogenesis.
[56] A. Olshen,et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. , 2006, Cancer research.
[57] R. Govindan,et al. Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B , 2005, Clinical Cancer Research.
[58] Sorin Draghici,et al. Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma , 2004, Clinical Cancer Research.
[59] J. Ellenberg,et al. NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization , 2003, The Journal of cell biology.
[60] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] J. Blumenstock,et al. Using gene expression ratios to predict outcome among patients with mesothelioma. , 2003, Journal of the National Cancer Institute.
[62] G. Scagliotti,et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] J. Shamash,et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] F. Khuri,et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. , 2000, Cancer research.
[65] F. Liddell,et al. The mortality of amphibole miners in South Africa, 1946-80. , 1992, British journal of industrial medicine.
[66] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[67] H. Ehrhart,et al. [Cancer and leukemia]. , 1957, Medizinische Klinik.